• 不 限
  • 期刊论文
  • 硕博论文
  • 会议论文
  • 报 纸
  • 英文论文
  2. 您的位置
  3. 首页
  4. 会议论文
  5. Dosimetric Evaluation and Treatment Outcome of Intensity Modulated Radiation Therapy After Doxorubic

Dosimetric Evaluation and Treatment Outcome of Intensity Modulated Radiation Therapy After Doxorubic

来源 :北京放射肿瘤学术论坛 | 被引量 : 0次 | 上传用户：lfastcandmuzi
【摘 要】
：
The dosimetric and clinical outcomes of intensity modulated radiation therapy for primary mediastinal large B-cell lymphoma after chemotherapy have not been reported previously, to our knowledge.This
【作 者】
：
Li-Ming Xu Bo Chen Shu-Nan Qi Hua Ren Jian-Rong Dai Ye-Xiong Li Hui Fang Jing Jin Wei-Hu Wang Shu-Lian Wang Yue-Ping Liu Yong-Wen Song Qing-Feng Liu 
【机 构】
：
Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Pe
【出 处】
：
北京放射肿瘤学术论坛
【发表日期】
：
2014年4期
下载到本地 , 更方便阅读
下载此文 赞助VIP
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
　　The dosimetric and clinical outcomes of intensity modulated radiation therapy for primary mediastinal large B-cell lymphoma after chemotherapy have not been reported previously, to our knowledge.This study describes the outcomes in such patients in detail for the first time.Despite the large target volume, intensity modulated radiation therapy gave excellent dose coverage and a favorable prognosis, with mild toxicity.
其他文献
1999-2008年中国乳腺癌术后放疗的临床流行病学研究
目的:了解中国乳腺癌术后放疗的变化,为改进治疗方式提供依据.方法:随机纳入国内不同地理区域的7家医院在1999-2008年收治的乳腺癌病人.每年随机选出一个月代表每家医院的这一年,对选定月份的所有住院乳腺癌病例进行分析.随机入选病例占7家医院10年间收治乳腺癌的9.3％ (4211/45200).本研究分析根治术后和保乳术后放疗的使用情况,放疗部位的变化情况.统计学分析采用Cochran-Armi
会议
乳腺癌放射治疗临床流行病学统计学分析
再程放疗乳腺癌脑转移患者的临床特点和预后分析
目的:回顾性分析乳腺癌脑转移再程放疗的疗效和影响预后的相关因素.方法:收集36例行再程放疗的乳腺癌脑转移患者,按L-Q模式计算等效生物剂量,计算总生存时间、中位局部控制时间,评估疗效、记录放疗不良反应.结果:全组患者中位年龄51.2岁(32.2-64.8岁),再程放疗后中位生存时间为9.1个月(1.3-56.8个月),6个月、12个月的总生存率分别为71.1％和33.9％,局部控制率分别为72.3
会议
乳腺癌脑转移患者再程放疗临床疗效预后因素
342例乳腺癌脑转移患者临床特点及预后因素分析
目的:探讨乳腺癌脑转移患者(Breast cancer brain metastases BCBM)预后生存的影响因素.方法:回顾分析2000年1月至2013年8月军事医学科学院附属医院收治的342例乳腺癌脑转移患者的临床病理资料、治疗措施等因素对BCBM患者生存期的影响.结果:全组患者脑转移的中位年龄47.8岁(25.3-79.9岁),从确诊乳腺癌到发生脑转移的中位时间为40.5个月(0-264
会议
乳腺癌脑转移患者临床病理预后因素
Definitive intensity-modulated radiotherapy compared with definitive 2D radiotherapy in cervical eso
Introduction: To compare definitive intensity-modulated radiotherapy (IMRT) with definitive 2D radiotherapy (2D-RT) in cervical esophageal squamous cell carcinoma (CESCC).Methods: A total of 101 patie
会议
cervical esophageal cancerTreatmentRadiotherapyIMRTSurvival
Pattern of failure in surgical treated patients with cervical esophageal squamous cell carcinoma
会议
Cervical esophageal squamous cell carcinomaPattern of failureSurgeryTreatment
Postoperative radiotherapy for completely resected Masaoka stage Ⅲ thymoma: a retrospective study of
Background The role of adjuvant radiotherapy (RT) for patients with stage Ⅲ thymoma after complete resection is not definite.Some authors have advocated postoperative RT after complete tumor resection
会议
thymomaradiationsurgeryfailure pattern
Epidemiologic Study of Radiotherapy Use in China in Patients With Breast Cancer Between 1999 and 200
This was a hospital-based, nationwide retrospective epidemiologic study, from 1999 to 2008 in China, of patients with breast cancer.A total of 1009 (27%) of the 3732 randomly selected patients receive
会议
Breast neoplasmEpidemiologic studyRadiotherapyUse rate
康莱特联合体部伽玛刀治疗28例局部晚期胰腺癌临床疗效观察
目的:观察康莱特注射液(Kanglaite injection,KLT)联合体部伽玛刀对局部晚期胰腺癌的治疗效果.方法:55例局部晚期胰腺癌患者,随机分为两组,研究组28例:采用体部伽玛刀治疗,PTV覆盖95％以上临床靶体积(Clinical target volume,CTV),等剂量曲线为50％～60％.肿瘤≤5cm的单次周边剂量3.6-4.5 Gy,肿瘤＞5cm的单次周边剂量3.0～4.0
会议
局部晚期胰腺癌康莱特注射液体部伽玛刀临床疗效
Survival benefit with salvage radiotherapy for patients with locoregionally recurrent extranodal NK/
The purposes of this study are to evaluate prognosis in patients with locoregionally recurrent extranodal nasal-type NK/T cell lymphoma (NKTCL) and to determine the value of salvage radiotherapy.Forty
会议
ChemotherapyLocoregional recurrenceNK/T cell lymphomaPrognosisRadiotherapyR
Survival Advantage With the Addition of Radiation Therapy to Chemotherapy in Early Stage Peripheral
Patients with early stage peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) have a poor prognosis, and data on early stage PTCL-NOS are lacking.This study describes the outcome in such pa
会议